Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
about
Pneumococcal vaccination during pregnancy for preventing infant infectionPredominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: A Systematic ReviewImpacts of the 13-Valent Pneumococcal Conjugate Vaccine in ChildrenEpidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factorsSerotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing invasive diseases from Shenzhen Children's HospitalPopulation structure of invasive Streptococcus pneumoniae isolates among Alaskan children in the conjugate vaccine era, 2001 to 2013.Genetic characterisation of Malawian pneumococci prior to the roll-out of the PCV13 vaccine using a high-throughput whole genome sequencing approachRealtime PCR is more sensitive than multiplex PCR for diagnosis and serotyping in children with culture negative pneumococcal invasive diseaseNovel clones of Streptococcus pneumoniae causing invasive disease in Malaysia.Factors associated with ceftriaxone nonsusceptibility of Streptococcus pneumoniae: analysis of South African national surveillance data, 2003 to 2010.Changes in capsule and drug resistance of Pneumococci after introduction of PCV7, Japan, 2010-2013.Carriage of Streptococcus pneumoniae and other respiratory bacterial pathogens in low and lower-middle income countries: a systematic review and meta-analysis.Increase in serotype 19A prevalence and amoxicillin non-susceptibility among paediatric Streptococcus pneumoniae isolates from middle ear fluid in a passive laboratory-based surveillance in Spain, 1997-2009.Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia.Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.The status of invasive pneumococcal disease among children younger than 5 years of age in north-west Lombardy, Italy.Identification of protective pneumococcal T(H)17 antigens from the soluble fraction of a killed whole cell vaccine.Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.Molecular characteristics of erythromycin-resistant Streptococcus pneumoniae from pediatric patients younger than five years in Beijing, 2010.Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendarThe burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe.Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes.Streptococcus pneumoniae from Palestinian nasopharyngeal carriers: serotype distribution and antimicrobial resistance.Initial effects of the National PCV7 Childhood Immunization Program on adult invasive pneumococcal disease in Israel.Invasive pneumococcal diseases in children and adolescents--a single centre experiencePrediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations.The pneumococcal polysaccharide capsule and pneumolysin differentially affect CXCL8 and IL-6 release from cells of the upper and lower respiratory tractThe Czech Surveillance System for Invasive Pneumococcal Disease, 2008-2013: A Follow-Up Assessment and Sensitivity Estimation.Seasonality of Pneumococcal Nasopharyngeal Carriage in Rural Gambia Determined within the Context of a Cluster Randomized Pneumococcal Vaccine TrialTemporal trends and clonal diversity of penicillin non-susceptible pneumococci from meningitis cases from 1996 to 2012, in Salvador, Brazil.Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention.Antimicrobial Susceptibility/Resistance of Streptococcus Pneumoniae.Timing of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in miceIn vitro activity of ceftaroline against clinical isolates of Streptococcus pneumoniae recovered in 43 U.S. medical centers during 2010-2011.Molecular Epidemiology of Streptococcus pneumoniae Isolates from Children with Recurrent Upper Respiratory Tract InfectionsParental knowledge, attitudes and perception of pneumococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assessment.A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia.Proteomic variation and diversity in clinical Streptococcus pneumoniae isolates from invasive and non-invasive sites
P2860
Q24186525-8F5B05F4-72FF-4F83-B1C9-0B88EFAE6F29Q26767290-3C84D781-B4EA-47CA-9F3B-C0FC103402B8Q26782280-850EAC36-24D1-43A3-BB21-38DE7269F409Q27685556-3AE15FB4-1BC9-4D4A-B282-40606125A48DQ28534411-E1593FFD-0F81-4DD5-91F7-93CFDBC048E4Q30151859-9EFD5B30-00BD-48EB-BE02-09AF892B087AQ30421183-86329BD3-CDB1-431A-ABB7-BB7291D4485AQ33533300-CA1AF107-C9DA-4CDE-A6B8-89C0D2F0BCDCQ33773494-5FE050FB-692E-4BD1-9594-575E98CB5827Q33798133-52E5D6BD-DCF2-416F-8B8E-279516A5A91FQ33816288-49076347-D8D5-4EE7-B924-76C72B1F1A7BQ33988997-89055674-39CF-4587-9F0F-CCD079B3A7A5Q34017120-BFEBE3AE-C8D1-490B-8C10-A660148174EAQ34026849-D07078F3-6B35-412A-B7F8-CDABE9ADA48CQ34194058-46E56E98-3741-4521-BD29-4A684AC8FE13Q34254800-4EF34153-3A8B-422F-AB37-7324876CD7ABQ34385066-442E691B-129A-4AED-A0D3-EB7062C35C12Q34407129-0A94F890-5675-4884-AB57-236FCDC602DFQ34436045-BB81203F-9404-4100-9C56-2AFB906B9D7DQ34466269-A159C081-69BB-4561-BB49-DD503A395AD1Q34484173-72B6EA3A-8B63-4CA3-8019-65A48A31D230Q34512593-CA8435BC-376B-4782-B90D-F85F92FFC7D2Q34798448-7AA9525F-89D1-487F-A8F0-280B31159332Q35005217-604EECE5-3FCA-41C4-A644-A3F0DEE9B3A8Q35067669-53ADD1EB-9A17-42EC-8F83-6FC6EBBF1397Q35091736-A40940CD-E102-46DF-8D25-4D901FAB25D7Q35119564-6197D257-5784-46EC-A34A-7FADE05C5B4BQ35124898-4D13A92F-F496-4C98-8007-5CB49985310AQ35130213-68DD064A-BBD6-4283-9E1C-118D035240C4Q35678552-F75019A6-5295-416E-A2E7-E2EF07746F12Q35679931-E4916D38-AF99-4832-AF51-6D6DB24269D1Q35724494-27A65128-7B56-44CB-9727-BD8308A4A2A2Q35826592-DF0A0EAB-A27F-4C35-AD0C-F0EB27A5CC4BQ35842871-A71C21EA-B906-4BD9-A7DB-971B704F7971Q35943992-ED0CB812-F56D-406F-AB17-708AE8D71DE5Q36018756-B767F4BD-0519-466D-ACD0-57A0AF14B497Q36077717-6AF9A43B-AAE5-4AE4-BAA2-C1F0F8692F6DQ36122153-757B4664-4648-42D8-92D1-160FD22F7201Q36306944-63AB2B74-3D1F-4DD3-8263-BAE17A9E77E3Q36390923-E97FD081-51BD-4022-9EDE-FDA0640CE00C
P2860
Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Burden of invasive pneumococca ...... for future conjugate vaccines.
@en
Burden of invasive pneumococca ...... for future conjugate vaccines.
@nl
type
label
Burden of invasive pneumococca ...... for future conjugate vaccines.
@en
Burden of invasive pneumococca ...... for future conjugate vaccines.
@nl
prefLabel
Burden of invasive pneumococca ...... for future conjugate vaccines.
@en
Burden of invasive pneumococca ...... for future conjugate vaccines.
@nl
P2093
P1476
Burden of invasive pneumococca ...... for future conjugate vaccines.
@en
P2093
Daniel J Isaacman
E David McIntosh
Ralf R Reinert
P304
P356
10.1016/J.IJID.2009.05.010
P577
2009-08-22T00:00:00Z